Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (181-190 of 196) with videos related to

Pageof 20
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulationJ Fareed, J M Walenga, D A Hoppensteadt, et al.
International Angiology : a Journal of the International Union of Angiology|July 25, 2000
Pharmacokinetics of argatroban in primates: evidence on endogenous uptakeS Ahmad, L H Yang, A Ahsan, et al.
The Canadian Journal of Cardiology|June 1, 1995
Successful treatment of heparin-associated thrombocytopenia and thrombosis using HirulogJ R Chamberlin, B Lewis, F Leya, et al.
Thrombosis Research|November 26, 1999
Laboratory monitoring of pentasaccharide in a dog model of hemodialysisD A Hoppensteadt, W P Jeske, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulationJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Acta Chirurgica Scandinavica. Supplementum|January 1, 1990
Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effectsJ Fareed, J M Walenga, M Lassen, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Pharmacologic profile of sulfamino-galactosaminoglycansR Pescador, R Porta, M Mantovani, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodiesS Ahmad, W P Jeske, J M Walenga, et al.
Thrombosis Research|July 1, 1991
Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (Enoxaparin) versus Dextran 70 in hip arthroplastyL C Borris, J V Sørensen, M R Lassen, et al.
Journal of Cardiac Surgery|January 28, 2005
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularizationO Iqbal, M Tobu, S Aziz, et al.
Pageof 20

Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulationJ Fareed, J M Walenga, D A Hoppensteadt, et al.
International Angiology : a Journal of the International Union of Angiology|July 25, 2000
Pharmacokinetics of argatroban in primates: evidence on endogenous uptakeS Ahmad, L H Yang, A Ahsan, et al.
The Canadian Journal of Cardiology|June 1, 1995
Successful treatment of heparin-associated thrombocytopenia and thrombosis using HirulogJ R Chamberlin, B Lewis, F Leya, et al.
Thrombosis Research|November 26, 1999
Laboratory monitoring of pentasaccharide in a dog model of hemodialysisD A Hoppensteadt, W P Jeske, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulationJ Fareed, J M Walenga, D A Hoppensteadt, et al.
Acta Chirurgica Scandinavica. Supplementum|January 1, 1990
Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effectsJ Fareed, J M Walenga, M Lassen, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Pharmacologic profile of sulfamino-galactosaminoglycansR Pescador, R Porta, M Mantovani, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodiesS Ahmad, W P Jeske, J M Walenga, et al.
Thrombosis Research|July 1, 1991
Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (Enoxaparin) versus Dextran 70 in hip arthroplastyL C Borris, J V Sørensen, M R Lassen, et al.
Journal of Cardiac Surgery|January 28, 2005
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularizationO Iqbal, M Tobu, S Aziz, et al.
Pageof 20